Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Who's to say the stock cannot or will not reverse split again?
This stock hasn't gone up an ages (relatively speaking) so "diluting on the way up" is rather non sequitur at this point in time.
I'll happily accept my mistakes if you can show me (on this thread) where I've posted incorrect information.
Good luck.
IMHO there will be more dilution and/or a "reverse split".
Restricted and unrestricted shares decreased and increased respectfully. My guess is there was some kind of share conversion form restricted shares to unrestricted shares. However I can't be 100% sure of that.
Yup, more dilution..
Looks like my prediction on dilution is coming truer and true by the week.
Of course, there are some here who want to live in la-la land and believe everything is peachy keen with with the way things are going.
There are some here who can't stand the fact I've been correct for months.
My guess is we might eventually see some kind of "reverse split" on this stock once PSRU finances everything (or as much) as they need to via stock sales.
Yup...dilution galore! My prediction a few months back of 1 billion shares in the float by the end of the year might be correct. I wouldn't be surprised to see 750 million shares in the float.
What's interesting is its the restricted shares which went up. Sounds like some company/financer probably got great rates for shares (which us plebian shareholders don't have access to).
Don't be surprised to see a "reverse split" down the line.
In 4 months, the float has gone from 89 million to almost 380 million..."only" about 290 million shares added to the float...LOL.
My guess is that Northstar Biotech invested in USRM knowing there was a good chance they might lose the Appeals case.
IMHO they believe that USRM has a future with whatever business model they plan on going with.
Thanks for the info.
Looks like one of my previous comments was at least partially correct - that USRM will try to expand in other areas.
I'm also hoping they expand their stem cell therapy/treatment/training on the human side internationally as well.
At least they want to proceed as a business and the veterinarian side is lucrative as well.
Hopefully USRM expands internationally where the FDA can't bogusly put an end to stem cell treatment.
I have seen this on their website:
http://us-stemcell.com/careers/
Current Openings
Marketing Intern – Sunrise, FL
Medical Physician – Kuwait
Mid-Level – Physician Assistant or Nurse Practitioner – Kuwait
I'm hoping USRM isn't a "one trick pony" and they have multiple avenues for revenues and they have "Plan B" as well.
According to USRM's website, they have other businesses however they don't breakdown revenues.
I don't see this as over yet - at least for the company.
As far as this case, it might be over.
We'll see.
Its quite quiet here given the relevancy of the news.
I expected more opining on this thread.
1)USRM still have other businesses.
2)The California Stem Cell case still might have some bearing, I don't know to be honest.
Overall, I agree. Had the Court of Appeals overturned the case, it would've been HUGE for USRM.
We'll see how USRM moves forward.
This ruling kind of let the air out of the balloon, so-to-speak.
That's because ostensibly IMHO it seems USRM never bothered to file an amendment to their original claims.
I do agree this is a of a blow to the USRM - at least when it comes to this part of their business.
Lets see how they, along with NorthStar Biotech move forward.
I'm hoping NorthStar Biotech/USRM have "Plan B" knowing the Court of Appeals might rule against USRM.
I'm also curious to see if Richard Jaffe, ESQ will blog on this result as well.
IMHO until the FDA says that stem cell therapy is safe, IMHO its going to be difficult for a number of these clinics to go forward.
We'll see.
Ok,
Reading into the judgement a little bit more.
Here (to me) is something of interest:
"On appeal, the Clinic adequately restates its position that the proper
benchmark is the basic function of the stromal-vascular fraction in adipose tissue (viz., “regeneration and repair”). We agree. Unlike the same surgical procedure exception, the 361 HCT/P exception and definition of homologous use do not require that an establishment remove an HCT/P from a patient and reimplant “such HCT/P” into the same patient.2
There is no reason, therefore, the court should not
compare stem cells to stem cells."
-At least the Appeals Court agrees with USRM on this part.
"The Clinic has consistently maintained that the stromal-vascular fraction serves a “regenerative function” inside adipose tissue. To determine the Clinic’s “objective intent” for the stromal-vascular fraction’s function after the procedure, we must look to the
Clinic’s marketing materials.
-USRM has to remarket its services IMHO to make it fit the definition of what they want to do.
Most important for me and where USRM can win on an appeal:
"The Clinic marketed the stromal-vascular fraction procedure for the
treatment of the plethora of conditions we described earlier. The district court was plainly correct that “providing a regenerative function in the donor is [not] the same basic function as restoring cell function, contributing to anti-inflammatory processes, and otherwise treating [a] litany of illnesses in the recipient.” "
That is potentially incorrect:
"Generate healthy cells to replace diseased cells (regenerative medicine). Stem cells can be guided into becoming specific cells that can be used to regenerate and repair diseased or damaged tissues in people."
https://www.mayoclinic.org/tests-procedures/bone-marrow-transplant/in-depth/stem-cells/art-20048117#:~:text=Generate%20healthy%20cells%20to%20replace,or%20damaged%20tissues%20in%20people.
Regardless, I'm not so sure what USRM can do from here.
I'm not so sure what catalyst we now have for USRM to move forward.
Is there something which I'm missing or is it indeed "game over" for USRM?
IMHO the Court of Appeals made the wrong decision when they said:
"We disagree: The procedure does not fall within the first exception because the biological material implanted into the patient is not the
same as that removed and the procedure does not fall within the second exception because the Clinic intends the stem cells to perform functions after the procedure beyond the basic functions the stem cells performed prior to the procedure."
Practically ANYTHING removed from the body and put back in is "not the same" - even in situation where its part of the first exception.
IMHO they also don't know how stem cells functions. What are "basic functions of stem cells"? Do they even know?
Ugh, this is frustrating.
I've been fully invested from the start. Haven't added nor removed any shares from my accounts.
Plan on waiting to see what the future holds.
Got it!
"Down down down you rollin
Watch the blood float in the muddy sewer"
"We Die Young" - Alice In Chains
At least we haven't seen any dilution the past month.
Best not to pay too much attention until there is some pertinent information out.
Everyone enjoy your Memorial Day weekend!
Yup..this is getting exciting.
Yup..this is getting exciting.
Sounds good to me..LOL!
Ok, got it!
We need some kind of facetious or sardonic emoji.
As you know, all prices predictions are meaningless until the various court cases play out.
As mentioned, one of the legal links was positive for at least the California case and the fact a company has invested in USRM is a good sign as well.
Now we have to wait it out.
Yes, I could've cashed out earlier but to me, the risk:reward ratio is worth holding.
I agree.
I think you are more optimistic than I am!
"But who knows." - that's the problem. Management isn't forthcoming with investors.
I wouldn't be surprised if that trend continues. How do they plan on paying salaries? IMHO more share dilution.
Maybe paying down debt will give them free cash flow for expenses and we can see share prices rise. Hope springs eternal however call me a skeptic.
So far (almost) every move has been to the downside.
I expect more dilution in the upcoming months. Hopefully I'm wrong though!
Thanks for the info.
These companies are getting tens of millions of shares for .0001 meanwhile shareholders get the shaft.
I wouldn't have minded giving PSRU $1,000 for 10,000,000 shares.
Maybe this stock will head to .0001 after all.
What a joke!
No change the past 2-3 weeks..what's going on? LOL
I'm staying optimistic however when I see unrelenting sell trades of 300,000 and 400,000 and 500,000 shares, it does get a bit disconcerting.
I guess we're in the same boat.
I hope you're right. LOL.
Not looking good here.
I've been in this stock for a while so I guess I'll see it to the "end".
We'll see what happens.
Yup...I'll hand it to those who held...unfortunately it wasn't me..darn!
Volume is 1:6 at buy:sell ratio so definitely some selling of shares.
Whole biotech market however is down the past few weeks so I'm not surprised to see selling.
I'm simply going to wait for the news to see what happens.
Thanks for the updates, appreciate it!